Boddy AV - Search Results

1

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.

Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, Errington J, Malik G, Hill CR, Chamberlain T, Boddy AV. Veal GJ, et al. Among authors: boddy av. Eur J Cancer. 2016 Mar;55:56-64. doi: 10.1016/j.ejca.2015.12.007. Epub 2016 Jan 12. Eur J Cancer. 2016. PMID: 26773420 Free PMC article. Clinical Trial.

2

Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma.

Veal G, Rowbotham S, Boddy A. Veal G, et al. Therapie. 2007 Mar-Apr;62(2):91-3. doi: 10.2515/therapie:2007020. Epub 2007 Jun 21. Therapie. 2007. PMID: 17582307

3

Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.

Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Chinnaswamy G, et al. Among authors: boddy av. Eur J Cancer. 2011 Jul;47(10):1556-63. doi: 10.1016/j.ejca.2011.03.008. Epub 2011 Apr 7. Eur J Cancer. 2011. PMID: 21482104

4

Pharmacogenetics of genes across the doxorubicin pathway.

Jamieson D, Boddy AV. Jamieson D, et al. Among authors: boddy av. Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1201-10. doi: 10.1517/17425255.2011.610180. Expert Opin Drug Metab Toxicol. 2011. PMID: 21919804 Review.

5

Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.

Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson AD, Boddy AV. Veal GJ, et al. Among authors: boddy av. Clin Cancer Res. 2013 Jan 15;19(2):469-79. doi: 10.1158/1078-0432.CCR-12-2225. Epub 2012 Oct 19. Clin Cancer Res. 2013. PMID: 23087409 Free PMC article. Clinical Trial.

6

Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.

Hill CR, Cole M, Errington J, Malik G, Boddy AV, Veal GJ. Hill CR, et al. Among authors: boddy av. Clin Pharmacokinet. 2014 Aug;53(8):741-51. doi: 10.1007/s40262-014-0153-2. Clin Pharmacokinet. 2014. PMID: 24968986 Free PMC article.

7

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.

Jamieson D, Sunter N, Muro S, Pouché L, Cresti N, Lee J, Sludden J, Griffin MJ, Allan JM, Verrill MW, Boddy AV. Jamieson D, et al. Among authors: boddy av. Eur J Cancer. 2017 Jan;71:15-24. doi: 10.1016/j.ejca.2016.10.035. Epub 2016 Dec 8. Eur J Cancer. 2017. PMID: 27940354

8

Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.

White-Koning M, Osborne C, Paci A, Boddy AV, Chatelut E, Veal GJ. White-Koning M, et al. Among authors: boddy av. Eur J Cancer. 2018 Mar;91:56-67. doi: 10.1016/j.ejca.2017.11.029. Epub 2018 Jan 12. Eur J Cancer. 2018. PMID: 29335155 Free PMC article.

9

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV. Bray J, et al. Among authors: boddy av. Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23. Br J Cancer. 2010. PMID: 20179710 Free PMC article.

10

Chemotherapy individualization.

Veal GJ, Coulthard SA, Boddy AV. Veal GJ, et al. Among authors: boddy av. Invest New Drugs. 2003 May;21(2):149-56. doi: 10.1023/a:1023517311879. Invest New Drugs. 2003. PMID: 12889736 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

176 results

Search Page

Filters